Evogene (NASDAQ: EVGN) furnishes Q2 2025 results press release and slides

Rhea-AI Filing Summary

Evogene Ltd. submitted a Form 6-K to provide investors with materials related to its second quarter 2025 results. The company states that it announced financial results for the quarter ended June 30, 2025, and furnished the full press release as an exhibit to this report.

Evogene also notes that it is holding a conference call on August 19, 2025 to discuss its quarterly results and has prepared a slide presentation for that call. Both the press release and the slide deck are attached as exhibits and incorporated by reference, and the GAAP financial statement tables in the press release are incorporated into certain existing Form F-3 and Form S-8 registration statements.

UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

On August 19, 2025, Evogene Ltd. (“Evogene”) announced its financial results for the second quarter ended June 30, 2025.  A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.

Evogene is holding a conference call on August 19, 2025 to discuss its quarterly results for the quarter ended June 30, 2025 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 19, 2025 EVOGENE LTD.
(Registrant)

By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Reports Second Quarter 2025 Financial Results.
99.2	Slide presentation for conference call of Evogene held on August 19, 2025, discussing Evogene’s quarterly financial results for the second quarter of 2025.

FAQ

What did Evogene (EVGN) file in this Form 6-K?

Evogene Ltd. filed a Form 6-K as a foreign private issuer to furnish its materials related to financial results for the second quarter ended June 30, 2025, including a press release and an investor slide presentation.

Which period do Evogene’s (EVGN) results in this Form 6-K cover?

The materials referenced in this Form 6-K relate to Evogene’s financial results for the second quarter ended June 30, 2025.

What exhibits are attached to Evogene’s (EVGN) August 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, a press release titled “Evogene Reports Second Quarter 2025 Financial Results,” and Exhibit 99.2, a slide presentation for an August 19, 2025 conference call discussing those quarterly results.

How are Evogene’s GAAP financial statements used in connection with this Form 6-K?

The GAAP financial statement tables contained in the attached press release are incorporated by reference into Evogene’s registration statements on Form F-3 and several Form S-8 registration statements and will be part of those registrations from the date this Form 6-K is submitted, unless later superseded.

Does this Evogene (EVGN) Form 6-K include a conference call announcement?

Yes. Evogene states it is holding a conference call on August 19, 2025 to discuss its quarterly results for the quarter ended June 30, 2025, and that it has prepared a slide presentation for investors as part of that call.

Where can investors find Evogene’s detailed second quarter 2025 results?

Investors can find the detailed second quarter 2025 results, including GAAP financial statement tables, in the press release furnished as Exhibit 99.1 to this Form 6-K.